Table 2.
EORTC QLQ-C30 and EORTC QLQ-BR23 questionnaire completion rates
| Ribociclib + letrozole n = 334 |
Placebo + letrozole n = 334 |
|||
|---|---|---|---|---|
| Patients on study at scheduled day, na | Patients on study at scheduled day with valid questionnaire within time window, n (%)b | Patients on study at scheduled day, na | Patients on study at scheduled day with valid questionnaire within time window, n (%)b | |
| EORTC QLQ-C30 completion rates | ||||
| Baseline | 334 | 324 (97.0) | 334 | 327 (97.9) |
| Cycle 3 Day 1 | 309 | 293 (94.8) | 298 | 291 (97.7) |
| Cycle 5 Day 1 | 283 | 269 (95.1) | 273 | 264 (96.7) |
| Cycle 7 Day 1 | 268 | 257 (95.9) | 259 | 255 (98.5) |
| Cycle 9 Day 1 | 248 | 237 (95.6) | 236 | 227 (96.2) |
| Cycle 11 Day 1 | 236 | 230 (97.5) | 215 | 202 (94.0) |
| Cycle 13 Day 1 | 216 | 206 (95.4) | 195 | 186 (95.4) |
| Cycle 15 Day 1 | 171 | 154 (90.1) | 136 | 133 (97.8) |
| Cycle 17 Day 1 | 118 | 110 (93.2) | 89 | 81 (91.0) |
| Cycle 19 Day 1 | 69 | 61 (88.4) | 45 | 41 (91.1) |
| Cycle 22 Day 1 | 20 | 17 (85.0) | 17 | 13 (76.5) |
| Cycle 25 Day 1 | 4 | 3 (75.0) | – | – |
| EORTC QLQ-BR23 completion rates | ||||
| Baseline | 334 | 324 (97.0) | 334 | 326 (97.6) |
| Cycle 3 Day 1 | 308 | 294 (95.5) | 298 | 289 (97.0) |
| Cycle 5 Day 1 | 283 | 269 (95.1) | 273 | 265 (97.1) |
| Cycle 7 Day 1 | 268 | 257 (95.9) | 259 | 254 (98.1) |
| Cycle 9 Day 1 | 248 | 237 (95.6) | 236 | 228 (96.6) |
| Cycle 11 Day 1 | 236 | 230 (97.5) | 215 | 203 (94.4) |
| Cycle 13 Day 1 | 216 | 206 (95.4) | 195 | 184 (94.4) |
| Cycle 15 Day 1 | 171 | 153 (89.5) | 136 | 131 (96.3) |
| Cycle 17 Day 1 | 118 | 110 (93.2) | 89 | 80 (89.9) |
| Cycle 19 Day 1 | 69 | 61 (88.4) | 45 | 42 (93.3) |
| Cycle 22 Day 1 | 20 | 17 (85.0) | 17 | 13 (76.5) |
| Cycle 25 Day 1 | 4 | 3 (75.0) | – | – |
EORTC QLQ-BR23 European Organisation for Research and Treatment of Cancer breast cancer-specific questionnaire, EORTC QLQ-C30 European Organisation for Research and Treatment of Cancer core quality-of-life questionnaire, QoL quality of life
aNumber of patients eligible to complete the questionnaire at the corresponding visit
bAt least one valid score among QoL, physical functioning, emotional functioning, and social functioning scores was required for the EORTC QLQ-C30 questionnaire